Department of Pathology and Cell Biology, Columbia University Irving Medical Center, 3959 Broadway, CHC 3-324, New York, NY, 10032, USA.
Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
BMC Infect Dis. 2023 Jan 13;23(1):26. doi: 10.1186/s12879-022-07959-2.
Mycolicibacter kumamotonensis is a slowly growing, non-chromogenic non-tuberculous mycobacteria (NTM) that was initially distinguished from the M. terrae complex in 2006. Since then it has been rarely reported as the cause of pulmonary and soft-tissue infections in both immunocompromised and immunocompetent patients.
We present a case of severe pulmonary disease due to Mycolicibacter kumamotonensis in a 57-year-old male who was immunocompetent at time of diagnosis, with a history of interstitial lung disease and a prior diagnosis of tuberculosis (TB). After initial treatment for TB in 2017, his condition stabilized until a recurrence in September 2021, leading to an evaluation for lung transplant in the setting of pulmonary fibrosis and emphysema which led to the identification of Mycolicibacter kumamotonensis. A lung transplant was completed, and the patient was successfully treated with a combination of Ethambutol, Azithromycin, and Rifabutin.
This represents the first case reported of M. kumamotonensis in a patient undergoing lung transplant, and the first case with rapid culture growth during identification of the organism (4 days). This report highlights the need for consideration of M. kumamotonensis as a pathogen in humans, with the potential for rapid growth in liquid media, and the importance of early identification to inform empiric therapy.
生金分枝杆菌是一种生长缓慢、非显色、非结核分枝杆菌(NTM),最初于 2006 年从 M. terrae 复合体中分离出来。此后,它在免疫功能低下和免疫功能正常的患者中,作为肺部和软组织感染的病原体,报道甚少。
我们报告了一例 57 岁免疫功能正常男性因生金分枝杆菌引起的严重肺部疾病,该患者有间质性肺病病史和先前的肺结核(TB)诊断。2017 年初次接受 TB 治疗后,病情稳定,直到 2021 年 9 月复发,导致在肺纤维化和肺气肿的情况下评估肺移植,从而鉴定出生金分枝杆菌。完成了肺移植,该患者成功地接受了乙胺丁醇、阿奇霉素和利福布汀联合治疗。
这是首例在接受肺移植的患者中报告的生金分枝杆菌病例,也是首例在鉴定该病原体时(4 天)快速培养生长的病例。该报告强调了需要考虑生金分枝杆菌作为人类病原体的可能性,其在液体培养基中具有快速生长的潜力,以及早期鉴定以告知经验性治疗的重要性。